Article info

Letter
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Free

Authors

  1. Correspondence to Professor Gary Tse, Tianjin Institute of Cardiology, Tianjin Medical University, Tianjin 300070, China; garytse86{at}gmail.com; Professor Qingpeng Zhang, School of Data Science, City University of Hong Kong, Hong Kong, China; qingpeng.zhang{at}cityu.edu.hk
View Full Text

Citation

Zhou J, Wang X, Lee S, et al
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study

Publication history

  • Received November 19, 2020
  • Revised November 23, 2020
  • Accepted November 29, 2020
  • First published December 4, 2020.
Online issue publication 
September 08, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.